Mean pre-therapeutic IP-10 serum levels in HNSCC patients were found to be significantly elevated compared to healthy controls (2,502.8 ± 1,098.5 pg/ml versus 1,488.3 ± 510.4 pg/ml) (71). This evidence concerns the gene CXCL10 and head and neck squamous cell carcinoma.